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OBJECTIVE: This work aimed to evaluate and correlate symptoms, biochemical blood test results and single
nucleotide polymorphisms for lactose intolerance diagnosis.
METHOD: A cross-sectional study was conducted in Fortaleza, Ceara´, Brazil, with a total of 119 patients, 54 of
whom were lactose intolerant. Clinical evaluation and biochemical blood tests were conducted after lactose
ingestion and blood samples were collected for genotyping evaluation. In particular, the single nucleotide
polymorphisms C4T-13910 and G4A-22018 were analyzed by restriction fragment length polymorphism/
polymerase chain reaction and validated by DNA sequencing.
RESULTS: Lactose-intolerant patients presented with more symptoms of flatulence (81.4%), bloating (68.5%),
borborygmus (59.3%) and diarrhea (46.3%) compared with non-lactose-intolerant patients (po0.05). We
observed a significant association between the presence of the alleles T-13910 and A-22018 and the lactose-
tolerant phenotype (po0.05). After evaluation of the biochemical blood test results for lactose, we found that
the most effective cutoff for glucose levels obtained for lactose malabsorbers was o15 mg/dL, presenting an
area under the receiver operating characteristic curve greater than 80.3%, with satisfactory values for sensitivity
and specificity.
CONCLUSIONS: These data corroborate the association of these single nucleotide polymorphisms (C4T-13910
and G4A-22018) with lactose tolerance in this population and suggest clinical management for patients with
lactose intolerance that considers single nucleotide polymorphism detection and a change in the biochemical
blood test cutoff from o25 mg/dL to o15 mg/dL.
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’ INTRODUCTION
Lactose intolerance (LI) is a common clinical syndrome
experienced by people worldwide. It comprises a variety of
symptoms, such as abdominal pain, flatulence, bloating,
borborygmus and osmotic diarrhea, caused by the break-
down of nondigested lactose by the gut microflora (1).
Nondigestion of lactose, frequently referred to as lactose
malabsorption (LM), is due to low expression of lactase. This
condition is also called hypolactasia or lactase nonpersis-
tence and is a physiologic feature occurring in most
mammals later in life (2). Lactase persistence varies among
different human populations, ranging from 95% in White
northern Europeans and North Americans to approximately
50% or less in South America and African countries, such as
Cameroon, Mali and South Africa, to nearly 0% in certain
Asian countries, including China (3,4).
Interestingly, not all patients with LM will develop
symptoms of LI. Therefore, usual LI management involves
excluding milk and milk products from the diet, which can
lead to an imbalance of calcium in the body (5,6).DOI: 10.6061/clinics/2016(02)06
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LI can be diagnosed through several approaches. The gold
standard is the measurement of lactase, sucrose and maltase
activity through intestinal biopsies. However, this method is
not commonly used due to its invasive nature (2). Other
tests, such as the lactose breath test, biochemical blood tests
and colorimetric-based reactions of biopsies (or quick tests),
are more frequently used (7,8).
The literature reports that in addition to biochemical blood
tests, genetic markers may be useful for LI diagnosis. Two
major markers have been identified so far: the single nucleotide
polymorphisms (SNPs) C4T-13910 and G4A-22018, located
upstream of the lactase gene. Both have been associated with
lactase persistence in several populations (4,9). In Brazil,
most studies have evaluated southeastern and southern
populations (10,11); only one study has investigated north-
eastern populations, but it lacked a comparative clinical
approach (12). Further studies are thus needed to investigate
whether these polymorphism associations occur in different
regions of Brazil, including populations in the Northeast.
In the present study, we had the following objectives: to
evaluate SNPs for LI diagnosis in a Brazilian population
from Fortaleza, Ceará, to correlate symptoms with biochem-
ical blood test results and to determine the associations
between cutoff values for the biochemical blood test and
both symptoms and SNPs.
’ MATERIALS AND METHODS
Location
The study was conducted at the Universidade Federal do
Ceará (UFC), Hospital Universitário Walter Cantidio, between
January and August 2010.
Study type and ethical review board approval
A cross-sectional study was conducted. The study protocol
was approved by the Internal Review Board’s Ethical Com-
mittee at Universidade Federal do Ceará (UFC), Hospital
Universitário Walter Cantidio (Protocol 294/2009). All indivi-
duals provided written informed consent.
Subjects screening and enrollment
Patients of both genders (mean age of 45.7 years old) were
chosen from the outpatient service. Clinical evaluation was
performed and a biochemical blood test for lactose tolerance
was conducted. Blood samples were also collected for
genotyping. The inclusion criteria were individuals of both
genders attending the service who claimed or were shown not
to be lactose intolerant but who lacked a definitive diagnosis.
The exclusion criteria were individuals with other chronic
clinical conditions, such as pancreatic insufficiency or lym-
phoma; individuals with recent use of illicit drugs, antibiotics,
antiarrhythmics, hormones, corticosteroids, chemotherapeu-
tics or other psychoactive drugs; and individuals who did not
have all samples collected or who chose not to participate.
Ultimately, a total of 119 subjects were enrolled in the study.
Case definition and clinical data
The case definition was stated as patients who had self-
diagnosed themselves as lactose intolerant, whereas the
controls had not. Prior to performance of any laboratory
tests, all patients were evaluated by a physician who checked
for symptoms that define the lactose-intolerant phenotype,
including borborygmus, abdominal pain, bloating, flatulence
and diarrhea after ingestion of dairy products.
Biochemical blood test
The lactose tolerance test was based on lactose ingestion.
This is a widespread test used in diverse settings, including
the hospital where the patients in this study were attended.
After an 8-hour fast, blood samples were collected for
baseline glucose determination. A 20% lactose solution was
then administered orally at a dose of 2 g/kg of body weight
(maximum dose of 50 g). Blood samples were again collected
after 30, 60, 90 and 120 min.
The usual interpretation is as follows: an increase of less
than 20 mg/dL in comparison to fasting glycemia is
classified as abnormal (lactose malabsorber), whereas an
increase above 25 mg/dL is considered normal and an
increase between 20 mg/dL and 25 mg/dL is considered
uncertain (13).
Genotyping
For each subject, 2 mL of blood was collected for DNA
sequencing and molecular analysis. Genomic DNA was
extracted from blood samples following the instructions for
the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA).
Polymorphism analysis was performed predominantly using
restriction fragment length polymorphism/polymerase
chain reaction (RFLP-PCR). DNA sequencing was performed
for 20% of the samples to confirm the RFLP-PCR results.
The RFLP-PCR analysis (C4T-13910 SNP – rs: 4988235 and
G4A-22018 SNP – rs: 182549) was based on the literature,
with certain modifications (14,15), using the primers sense-50-
GAGTGTAGTTGTTAGACGGAG-30 and antisense-50-ATCA
AACATTATACAAATGCAAC-3’ (for C4T-13910 SNP) or sense-
5’-AACAGGCACGTGGAGGAGTT-3’ and antisense-5’-TTGA
GTAGCTGGGACCACAA-3’ (for G4A-22018 SNP) under the
following PCR conditions: 95oC for 5 min, followed by 40 cycles
of 95oC for 30 s, 54oC (for C4T-13910 SNP) or 65
oC (for
G4A-22018 SNP) for 30 s and 72
oC for 1 min. The PCR products
were then digested with CviIJ (14) or HhaI (15) and analyzed
using 5% agarose gel electrophoresis. Digestion with CviIJ
revealed fragments of 122 bp, 47 bp and 34 bp in the case of the
C allele and fragments of 122 bp, 47 bp and 41 bp in the case of
the Tallele. Meanwhile, digestion withHhaI revealed fragments
of 264 bp and 170 bp in the case of the G allele and an
undigested fragment of 434 bp in the case of the A allele
(Supplemental Figures 1A and 2A).
For DNA sequencing, the PCR products were purified using
a QIAquick PCR Purification Kit (Qiagen, Valencia, CA) and
were amplified with one of each pair of primers previously used
(sense or antisense) using BigDye Terminator Sequencing Buffer
with appropriate labeled ddNTPs (Applied Biosystems, Weiter-
stadt, Germany) under the following conditions: 96oC for 1 min,
followed by 40 cycles of 96oC for 30 s, 54oC (for C4T-13910
polymorphism) or 65oC (for G4A-22018 polymorphism) for
30 s and 60oC for 4 min. After the reaction, isopropanol
and 60% ethanol washes were performed and formamide
was added, after which the samples were assessed using
an ABI Prism 3100-Avant sequencer (Applied Biosystems,
Weiterstadt, Germany) and Sequence Scanner v1.0 software
(Supplemental Figures 1B and 2B).
Statistical analysis
The data were double entered by two different persons
and validated by a third person using Access and Excel 2007
software (Microsoft Inc., Redmond, WA). STATA version 8.0
software (Stata Corp LP, College Station, TX) was utilized for
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statistical analysis. Associations between conditions were
verified by Pearson’s chi-square or Fisher’s exact test.
Receiver operating characteristic (ROC) curves were utilized
to determine which cutoff (15, 20, or 25 mg/dL) would lead
to better values for sensitivity and specificity for a diagnosis
of LI.
’ RESULTS
Characterization of the subjects enrolled in the
study protocol
All sociodemographic parameters, such as the gender, age,
ethnic group, educational status and geographic origin of the
subjects included in the study, are shown in Table 1. Gender
and age were discriminated by case and control group
allocation, with no significant difference between them
according to Fisher’s exact test (p40.05).
Clinical aspects of the lactose-intolerant phenotype
The presence of symptoms that define the lactose-intoler-
ant phenotype was assessed and compared between the case
and the control groups. Overall, the most prevalent
symptoms were flatulence (81.5%), bloating (68.5%), borbor-
ygmus (59.3%) and diarrhea (46.3%). Individually, flatulence,
bloating, borborygmus, diarrhea and constipation symptoms
were significantly associated with the case group according
to Pearson’s chi-squared test (po0.05), whereas weight loss
was not (Table 2), suggesting an efficient correlation with the
lactose-intolerant phenotype.
Biochemical blood testing and the lactose-
intolerant phenotype
To improve the efficacy of the biochemical blood test, the
lactose-intolerant phenotype described previously was tested
for correlations with different cutoffs (deltao15 mg/dL, delta
o20 mg/dL and deltao25 mg/dL) for the test for evaluation
of lactose tolerance. Using delta o15 mg/dL as a positive
result, 85.2% of the subjects with the lactose-intolerant
phenotype were classified as lactose malabsorbers. For delta
o20 mg/dL and deltao25 mg/dL, we found that 90.7% and
92.6% of subjects were lactose absorbers, respectively (Table 3).
The delta o15 mg/dL cutoff was significantly associated
with the lactose-intolerant phenotype according to Fisher’s
exact test, which showed an odds ratio (OR) of 17.61 (95% CI:
6.88–45.06). This result provided the best cutoff in terms of
Table 1 - Sociodemographic parameters in the study population from northeastern Brazil.
Sociodemographic parameter Cases (%) n=54 Controls (%) n=65 n (%) n=119
Gender
Male 24 (44.5) 30 (46.2) 54 (45.4)
Female 30 (55.5) 35 (53.8) 65 (54.6)
Age (years)
o15 0 (0) 2 (3.1) 2 (1.7)
15–24 4 (7.4) 5 (7.7) 9 (7.5)
25–34 10 (18.5) 12 (18.4) 22 (18.5)
35–44 7 (13.0) 12 (18.4) 19 (16.0)
45–54 16 (29.6) 16 (24.6) 32 (26.9)
55–64 10 (18.5) 11 (17.0) 21 (17.6)
65 or more 7 (13.0) 7 (10.8) 14 (11.8)
Ethnic group*
Browns 65 (54.6)
Whites 54 (45.4)
Blacks 0 (0)
Educational status
Elementary school 4 (3.3)
Middle school 2 (1.7)
High school 45 (37.8)
Undergraduate school 51 (42.9)
Graduate school 17 (14.3)
Geographic origin
Fortaleza (capital of Ceara´ State) 109 (91.6)
Ceara´ Countryside 10 (8.4)
Total 119 (100)
*Based on ethnic self-categorization as a White, Brown or Black Brazilian (13).
Table 2 - Distribution of clinical symptoms among the case and
control groups in the study population from northeastern Brazil.
Symptom Cases n (%) Controls n (%) p-value*
Flatulence
No 10 (18.5) 35 (53.8) 0.0001
Yes 44 (81.5) 30 (46.2)
Total 54 (100) 65 (100)
Bloating
No 17 (31.5) 34 (52.3) 0.0264
Yes 37 (68.5) 31 (47.7)
Total 54 (100) 65 (100)
Borborygmus
No 22 (40.7) 42 (64.6)
Yes 32 (59.3) 23 (35.4) 0.0264
Total 54 (100) 65 (100)
Diarrhea
No 29 (53.7) 49 (75.4)
Yes 25 (46.3) 16 (24.6) 0.0196
Total 54 (100) 65 (100)
Constipation
No 32 (59.3) 46 (70.8) 0.0015
Yes 22 (40.7) 19 (29.2)
Total 54 (100) 65 (100)
Weight loss
No 41 (75.9) 53 (81.5) 0.5028
Yes 13 (24.1) 12 (18.5)
Total 54 (100) 65 (100)
* Fisher’s exact test
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sensitivity (85.2%) and specificity (75.4%) values, whereas
delta o20 mg/dL yielded respective values of 90.7% and
55.4% and delta o25 mg/dL yielded respective values of
92.6% and 41.5%. For the ROC curves, delta o15 mg/dL
provided an area under the curve of 80.3%, with 85.2%
sensitivity and 75.8% specificity (Figure 1A), whereas delta
o20 mg/dL and delta o25 mg/dL provided areas of 73.1%
and 67.1%, respectively (Figures 1B and 1C).
Genetic evaluation of the SNPs C4T-13910
AND G4A-22018
The frequency of the C4T-13910 polymorphism among
subjects with the lactose-tolerant phenotype was 60% (39/
65), with 35 CT-13910 genotypes and 4 TT-13910 genotypes.
These genotypes were also observed in 24% (13/54) of the
subjects with the lactose-intolerant phenotype, presenting 12
CT-13910 genotypes and 1 TT-13910 genotype. In contrast, the
CC-13910 genotype was found in 76% (41/54) of the subjects
with the lactose-intolerant phenotype, but only in 40% (26/
65) of the lactose-tolerant phenotype group (Table 4). There
was a significant correlation between the CC-13910 genotype
and the lactose-intolerant phenotype as well as between
the CT-13910 and TT-13910 genotypes and the lactose-tolerant
phenotype according to Fisher’s exact test (po0.001). We
found an OR of 4.731 (95% CI: 2.13–10.50) for subjects of both
genders for the lactose-intolerant phenotype if they pre-
sented with the CC-13910 genotype.
The frequency of the G4A-22018 SNP was 61.5% (40/65) in
the lactose-tolerant phenotype group, with 36 subjects
presenting with GA-22018 genotypes and 4 presenting with
AA-22018 genotypes. These genotypes were also observed in
33.3% (18/54) of subjects from the lactose-intolerant pheno-
type group, who presented with 17 GA-22018 genotypes and 1
AA-22018 genotype. In contrast, the GG-22018 genotype was
found in 66.7% (36/54) of subjects with the lactose-intolerant
phenotype, but not in 38.5% (25/65) of the lactose-tolerant
phenotype group (Table 4). There was a significant correla-
tion between the GG-22018 genotype and the lactose-intoler-
ant phenotype as well as between the GA-22018 and AA-22018
genotypes and the lactose-tolerant phenotype according to
Fisher’s exact test (p=0.005). We found an OR of 3.20 (95% CI:
1.50–6.81) for subjects of both genders for the lactose-
intolerant phenotype if they presented with the GG-22018
genotype.
There was no difference between observed and expected
allele frequencies for the C4T-13910 SNP (p=0.911 and
p=0.081 for the case and control populations, respectively)
and G4A-22018 SNP (p=0.528 and p=0.056 for the case and
control populations, respectively), which is consistent with
Hardy-Weinberg equilibrium.
Genetic polymorphisms and biochemical blood
test correlations
Based on these results, we chose the SNP CT-13910 to
perform a statistical analysis of the correlations between the
genetic data and the three evaluated biochemical blood test
cutoffs. For this analysis, we classified CT-13910 and TT-13910
as lactose-tolerant genotypes and CC-13910 as a lactose-
intolerant genotype.
Defining delta o15 mg/dL as LM, 76.9% (40/52) of the
subjects with a lactose-tolerant genotypewere classified as lactose
absorbers, and 74.6% (50/67) of those with a lactose-intolerant
Table 3 - Association between different cutoffs for the biochemical blood test and the case and control groups.
Different cutoffs (Delta = maximum – basal glucose concentration) Cases n (%) Controls n (%) p-value*
Delta o15 mg/dL
Lactose absorber 8 (14.8) 49 (75.4) o0.0001
Lactose malabsorber 46 (85.2) 16 (24.6)
Total 54 (100) 65 (100)
Delta o20 mg/dL
Lactose absorber 5 (9.3) 36 (55.4) o0.0001
Lactose malabsorber 49 (90.7) 29 (44.6)
Total 54 (100) 65 (100)
Delta o25 mg/dL
Lactose absorber 4 (7.4) 27 (41.5) o0.0001
Lactose malabsorber 50 (92.6) 38 (58.5)
Total 54 (100) 65 (100)
* Fisher’s exact test
Figure 1 - Receiver operating characteristic curve and corresponding area under the curve for the diagnosis of lactose intolerance using
different cutoffs for a positive biochemical blood test: (A) deltao15 mg/dL, (B) deltao20 mg/dL and (C) deltao25 mg/dL, considering
the lactose-intolerant phenotype.
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genotype were classified as lactose malabsorbers. Using delta
o20 mg/dL as the cutoff, 63.5% (33/52) of the subjects with
a lactose-tolerant genotype were classified as lactose absor-
bers and 88.1% (59/67) of those with a lactose-intolerant
genotype were classified as lactose malabsorbers. Finally, for
the cutoff of deltao25 mg/dL, 48.1% (25/52) of the subjects
with a lactose-tolerant genotype were classified as lactose
absorbers and 91.0% (61/67) of those with a lactose-
intolerant genotype were classified as lactose malabsorbers.
We observed a significant association with all cutoffs
according to Fisher’s exact test (Table 5).
According to the area under the ROC curve (75.7%), the
cutoff that presented better values for sensitivity and
specificity was delta o15 mg/dL. Using this cutoff, an
individual could be classified as lactose intolerant with
sensitivity and specificity of 74.6% and 76.9%, respectively
(Figure 2A). In addition, for the cutoff of delta o20 mg/dL,
sensitivity and specificity were 88.1% and 63.4%, respectively
and for delta o25 mg/dL, sensitivity and specificity were
91% and 48.1, respectively (Figures 2B and 2C).
The same evaluation of the G4A-22018 polymorphism
indicated similar correlation results (Supplemental Figure 3
and Supplemental Table 1).
Lactose intolerance management flow chart
To optimize the clinical management of LI, we propose a
flow chart for its diagnosis. As a first step, patients should
undergo biochemical blood tests for evaluation of LM,
interpreting delta o15 mg/dL as positive and delta 415
mg/dL as negative. If they have self-diagnosed symptoms of
LI and have a positive biochemical blood test, they can be
classified as lactose intolerant. In contrast, if they do not
present with symptoms, they could be classified as lactose
malabsorbers.
After excluding milk products from their diets for
3 months, individuals who continue to present with symp-
toms must be classified as lactose malabsorbers by secondary
causes, whereas those who do not show symptoms after
dietary exclusion should readopt their normal diet. If the
symptoms do not return, other causes of malabsorption must
be considered. If the symptoms return, genotyping of the
subjects should be performed. The CC-13910 genotype
indicates primary hypolactasia, whereas the presence of
the T allele indicates secondary causes of malabsorption
(Figure 3).
’ DISCUSSION
LI is one of the most prevalent problems in gastrointestinal
clinical practice (2). A misunderstanding of the terminology
and a lack of knowledge about the multiple factors involved
in the onset of symptomatology are two issues reported in
the literature (1,4).
The use of a biochemical blood test to assess LM is useful,
although not conclusive, as not all malabsorbers develop
symptoms of LI. Many factors contribute to the development
of symptoms in a patient who is a lactose malabsorber: the
lactose dosage, diet, the microbiota and lactase activity in the
mucosa. In this context, the clinical significance of LM or LI
may be overestimated (1,6).
However, many non-malabsorbers diagnose themselves as
lactose intolerant (1,6). According to the new National
Institutes of Health definition, LI specifically refers to the
development of symptoms after blinded lactose challenge in
an individual with LM (16). We believe that it is necessary to
standardize a specific clinical protocol for patients suspected
of having LI, along with optimized tests for LM assessment.
The present study proposes a change in the glucose level
cutoff from o25 mg/dL to o15 mg/dL, as measured after
lactose challenge, leading to greater levels of sensitivity and
specificity.
Table 4 - Correlation between the genotypes for the single
nucleotide polymorphisms C4T-13910 and G4A-22018 and the
case and control groups.
Genotype Cases n (%) Controls n (%) p-value*
C4T-13910 SNP
TT 1 (1.8) 4 (6.2) o0.0001
CT 12 (22.3) 35 (53.8)
CC 41 (75.9) 26 (40.0)
Total 54 (100) 65 (100)
G4A-22018 SNP
AA 1 (1.8) 4 (6.1) 0.0031
GA 17 (31.5) 36 (55.4)
GG 36 (66.7) 25 (x)
Total 54 (100) 65 (100)
SNP: Single nucleotide polymorphism
*Fisher’s exact test
Table 5 - Correlation between the biochemical blood test with different cutoffs (delta o15 mg/dL, delta o20 mg/dL or
delta o25 mg/dL) and the genotype for the single nucleotide polymorphism C4T-13910.
Cutoff (Delta = maximum – basal glucose concentrations) C4T-13910 SNP p-value*
Lactose tolerant n (%) Lactose intolerant n (%)
Delta o15 mg/dL
Lactose absorber 40 (76.9) 17 (25.4) o0.0001
Lactose malabsorber 12 (23.1) 50 (74.6)
Total 52 (100) 67 (100)
Delta o20 mg/dL
Lactose absorber 33 (63.5) 8 (11.9) o0.0001
Lactose malabsorber 19 (36.5) 59 (88.1)
Total 52 (100) 67 (100)
Delta o25 mg/dL
Lactose absorber 25 (48.1) 6 (9.0) o0.0001
Lactose malabsorber 27 (51.9) 61 (91.0)
Total 52 (100) 67 (100)
SNP: Single nucleotide polymorphism
*Fisher’s exact test
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There is a strong association between lactase persistence
and ethnicity. Caucasians are more lactase persistent, whereas
blacks are often hypolactasic (1). In a study performed in
a Brazilian population, the investigators concluded that the
T allele from the C4T-13910 polymorphism had similar
frequencies among Brazilian White and Brown populations,
whereas it was absent among Japanese Brazilians (17).
Our study investigated a population composed of Whites
(45.4%) and Browns (54.6%) from the State of Ceará, located
in northeastern Brazil. These frequencies are consistent
with the ethnic percentage population distribution in this
state (18).
Figure 2 - Receiver operating characteristic curve and corresponding area under the curve for the diagnosis of lactose intolerance using
different cutoffs for a positive biochemical blood test: (A) deltao15 mg/dL, (B) deltao20 mg/dL and (C) deltao25 mg/dL, considering
the single nucleotide polymorphism C4T-13910.
Figure 3 - Flow chart suggesting a clinical protocol for the diagnosis of lactose intolerance by combining clinical symptoms, biochemical blood
test results and single nucleotide polymorphism detection. See text for detailed description.
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The use of genetic tests has been proposed for LI diagnosis
in different populations to differentiate primary hypolactasia
from secondary causes (19,20). Our results showed that a CC
genotype is associated with LI in the population studied in
the Brazilian Northeast. Conversely, the T allele (CT and TT
genotypes) is associated with the lactose-tolerant phenotype.
Such findings are important and suggestive for composing
a future diagnostic test for hypolactasia. As already shown in
other populations (9,10,21), our results also show that
the C4T-13910 SNP is in significant agreement with the
G4A-22018 SNP, relating CC to GG, GA to CT, and TT to AA
genotypes.
In this study, the identification of individuals as genetically
lactose intolerant (CC or GG), although classified as lactose
tolerant based on biochemical blood tests and reported
symptoms, could be explained by a slow decline in the tissue
concentration of lactase, with hypolactasia developing later in
life. More studies should be conducted to determine the factors
involved in the variation of lactase expression throughout life.
Although there is a clear association between the SNPs (C4T-
13910 and G4A-22018) and lactose tolerance, the complete
mechanism of lactase expression still needs to be elucidated.
The interaction of transcription factors is the focus of new
studies that may clarify when subjects with hypolactasic
genotypes will develop LI symptoms (22). In contrast, the
identification of individuals who were genetically lactose
tolerant (presence of the T-13910 or A-22018 allele) but who
presented with symptoms related to lactose ingestion and
with biochemical blood test outcomes classifying them as
malabsorbers may suggest a secondary cause of hypolactasia
(such as celiac disease, gastroenteritis, parasites, or Crohn’s
disease, among others) related to lesions of the intestinal
mucosa (10). In our study, we generally observed that such
individuals were older (up to 35 years) (data not shown).
Despite the existence of a few studies that investigated
these SNPs in Brazil (10-12), it is well known that large
continental-dimension countries, such as Brazil, might show
different SNP prevalences. Several recent studies from India,
Israel and Colombia have also found different associations
between SNPs and chemical test results among different
ethnic groups within the same region (21,23-25). Moreover, a
study on African populations highlighted the limitations of
the C4T-13910 polymorphism among people with non-
European ancestry (26). In this context, a Brazilian study
indicated that G4A-22018, but not C4T-13910, is the SNP that
must be employed for the analysis of LI in Brazilians of
Japanese descent (27). These observations highlight the need
for more studies in the Northeast of Brazil.
Many studies have attempted to assess SNPs’ associations
with breath test and lactose tolerance test results (25,28-30).
The present study is the first study to evaluate correlations
between different cutoffs for glucose levels in biochemical
blood tests for lactose tolerance and genotyping of the SNPs
C4T-13910 and G4A-22018 upstream of the lactase gene. After
ROC curve analysis, the most applicable cutoff for LM
diagnosis was delta o15 mg/dL. As the cutoff is increased
(to o20 mg/dL or o25 mg/dL), the sensitivity value of the
test becomes higher, whereas the specificity becomes lower. It
is important to note that the biochemical blood test does not
represent the gold standard for diagnosis of LM, as the
intestinal microbiota, the lactose dosage, individual meta-
bolic differences and diet might influence the results; the
measurement of lactase activity through intestinal biopsies is
the ideal approach, although invasive (6).
Disagreements between biochemical and genotypic tests
(21) show that it is important to evaluate clinical aspects and
to consider factors that cause LI other than the genetic basis.
In fact, certain patients may not develop LI, despite their
genetic basis; these individuals may develop symptoms later
in life. We believe that these considerations are extremely
important when assessing patients with gastrointestinal
symptoms similar to LI.
Other studies have proposed a flow chart, but biochemical
blood testing following lactose ingestion and glucose level
measurement are rarely evaluated (6,31). Here, we present a
diagnostic algorithm for LI, considering biochemical blood
test results, clinical symptoms, and genotyping of the SNPs
C4T-13910 and G4A-22018. This protocol will undoubtedly be
very useful in settings where a breath test is not performed
routinely.
This study has certain limitations, such as the lack of a
comparison between the biochemical blood test and a breath
test and the small sample number; overcoming these
limitations would provide a more precise conclusion about
the usefulness of current LM tests. This is therefore a pilot
study that must be performed in other settings. Furthermore,
investigation of other factors that modulate LI symptom
onset in a cohort setting must be performed in future studies.
This study corroborates the association of the SNPs C4T-
13910 and G4A-22018 with lactose tolerance in a population
located in northeastern Brazil (OR=4.73 and OR=3.2,
respectively). The data from this study suggest changing
the delta cutoff for the biochemical blood test for LI from
o25 mg/dL to o15 mg/dL based on the ROC curve using
the lactose-intolerant phenotype and genetic polymorphism.
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